[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100663107":3},{"organization":4,"outcomesModule":7,"designInfo":52,"detailedDescription":51,"studyPopulation":51,"armGroups":58,"interventions":70,"overallOfficials":51,"centralContacts":83,"locations":51,"responsibleParty":89,"collaborators":51,"id":91,"slug":92,"hasResults":93,"nctId":94,"briefTitle":95,"officialTitle":96,"acronym":51,"eligibilityCriteria":97,"healthyVolunteers":93,"sex":98,"minAge":99,"maxAge":51,"enrollmentInfo":100,"targetDuration":51,"studyType":103,"phases":104,"briefSummary":106,"conditions":107,"keywords":51,"overallStatus":109,"whyStopped":51,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":114,"completionDateStruct":116,"leadSponsor":118,"locationsCount":51},{"fullName":5,"class":6},"Genfleet Therapeutics (Shanghai) Inc.","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":17,"otherOutcomes":51},[9,13],{"measure":10,"description":11,"timeFrame":12},"Progression-free survival (PFS)","Progression-free survival (PFS) assessed by blinded independent central review (BICR) according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1","Up to approximately 2 years",{"measure":14,"description":15,"timeFrame":16},"Overall survival（OS）","Overall survival","Up to approximately three and a half years",[18,21,24,27,30,33,36,39,42,45,48],{"measure":19,"description":20,"timeFrame":12},"Progression-free survival (PFS) assessed by the investigator","PFS assessed by the investigator according to RECIST v1.1",{"measure":22,"description":23,"timeFrame":16},"Objective response rate (ORR)","Objective response rate (ORR) assessed by BICR and the investigator according to RECIST v1.1",{"measure":25,"description":26,"timeFrame":16},"Incidence and severity of adverse events (AEs) and serious adverse events (SAEs)","Incidence and severity of adverse events (AEs) and serious adverse events (SAEs) according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) v6.0",{"measure":28,"description":29,"timeFrame":16},"Incidence and severity of adverse events (AEs) and serious adverse events (SAEs) leading to treatment modifications","Incidence and severity of AEs\u002FSAEs leading to treatment discontinuation, treatment interruption, and dose reduction",{"measure":31,"description":32,"timeFrame":16},"Changes in scores assessed by the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30)","The EORTC-QLQ-C30 is a 30-item cancer-specific instrument consisting of 5 functional scales (physical, role, emotional, social and cognitive), 9 symptom scales\u002Fitems (fatigue, nausea\u002Fvomiting, general pain, dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties) and a global health status scale. Participants rate items on a four-point scale, with 1 as \"not at all\" and 4 as \"very much.\" For functional scales, higher scores indicate better functioning, while for symptom scales\u002Fitems, higher scores indicate worse symptoms.",{"measure":34,"description":35,"timeFrame":16},"Peak Plasma concentration (Cmax) of GFH375","Peak Plasma concentration (Cmax) of GFH375 following combination treatment",{"measure":37,"description":38,"timeFrame":16},"Disease control rate (DCR)","Disease control rate (DCR) assessed by BICR and the investigator according to RECIST v1.1",{"measure":40,"description":41,"timeFrame":16},"Time to response (TTR)","Time to response (TTR) assessed by BICR and the investigator according to RECIST v1.1",{"measure":43,"description":44,"timeFrame":16},"Duration of response (DoR)","Duration of response (DoR) assessed by BICR and the investigator according to RECIST v1.1",{"measure":46,"description":47,"timeFrame":16},"Changes in scores assessed by the EORTC Colorectal Cancer-Specific Quality of Life Questionnaire 29 (EORTC QLQ-CR29)","The EORTC QLQ-CR29 is a supplementary questionnaire module to be employed in conjunction with the QLQ-C30. It incorporates 4 multiitem scales and 19 single-items assessing a range of symptoms and problems common among patients with colorectal cancer. All of the scales and single-item measures range in score from 0 to 100. A high score for the functional scale and functional single-items represents a high level of functioning, whereas a high score for the symptom scales and symptom single-items represents a high level of symptomatology or problems.",{"measure":49,"description":50,"timeFrame":16},"Trough Plasma concentration (Ctrough) of GFH375","Trough Plasma concentration (Ctrough) of GFH375 following combination treatment",null,{"allocation":53,"interventionModel":54,"interventionModelDescription":51,"primaryPurpose":55,"observationalModel":51,"timePerspective":51,"maskingInfo":56},"RANDOMIZED","PARALLEL","TREATMENT",{"masking":57,"maskingDescription":51,"whoMasked":51},"NONE",[59,64],{"label":60,"type":61,"description":51,"interventionNames":62},"GFH375 + Cetuximab","EXPERIMENTAL",[63],"Drug: GFH375 + Cetuximab",{"label":65,"type":66,"description":51,"interventionNames":67},"The investigator's choice of treatment","ACTIVE_COMPARATOR",[68,69],"Drug: Fruquintinib","Drug: Trifluridine and Tipiracil",[71,75,79],{"type":72,"name":60,"description":73,"armGroupLabels":74,"otherNames":51},"DRUG","GFH375：600 mg orally, once daily Cetuximab ：500 mg\u002Fm² intravenously every 2 weeks",[60],{"type":72,"name":76,"description":77,"armGroupLabels":78,"otherNames":51},"Fruquintinib","35 mg\u002Fm² orally twice daily (max single dose 80 mg) on Days 1-5 and Days 8-12",[65],{"type":72,"name":80,"description":81,"armGroupLabels":82,"otherNames":51},"Trifluridine and Tipiracil","5 mg orally once daily on Days 1-21",[65],[84],{"name":85,"role":86,"phone":87,"phoneExt":51,"email":88},"Fengying PENG","CONTACT","+86 21 6882 1388","fypeng@genfleet.com",{"type":90,"investigatorFullName":51,"investigatorTitle":51,"investigatorAffiliation":51,"oldNameTitle":51,"oldOrganization":51},"SPONSOR","100663107","phase-3-gfh375-plus-cetuximab-vs-investigators-choice-of-treatment-in-kras-g12d-mutant-refractory-metastatic-colorectal-cancer-100663107",false,"NCT07913360","GFH375 Plus Cetuximab vs Investigator's Choice of Treatment in KRAS G12D-Mutant Refractory Metastatic Colorectal Cancer","A Multicenter, Open-label, Randomized Controlled Phase III Study Evaluating the Efficacy and Safety\u002FTolerability of GFH375 in Combination With Cetuximab Versus Investigator's Choice of Treatment in Patients With KRAS G12D Mutant Metastatic Colorectal Cancer Refractory to Oxaliplatin, Fluoropyrimidines, and Irinotecan","Inclusion Criteria:\n\n* Willing to participate in the study and provide written informed consent\n* Age ≥18 years at the time of signing informed consent; no sex restriction\n* Histologically or cytologically confirmed colorectal cancer (CRC)\n* KRAS G12D mutation confirmed by the central laboratory\n* Disease progression or intolerance during or after prior systemic anticancer therapy\n* At least one measurable lesion\n* Eastern Cooperative Oncology Group Performance Status (ECOG PS) score of 0-1\n* Investigator-assessed life expectancy ≥12 weeks\n* Adequate function of major organs\n* In the investigator's judgment, the participant is able to communicate effectively, adhere to the scheduled follow-up visits, and comply with the protocol requirements\n\nExclusion Criteria:\n\n* Other malignancy that has progressed or required treatment within 3 years prior to randomization\n* Known presence of other actionable\u002Ftargetable driver gene alterations\n* Leptomeningeal metastases, spinal cord compression, or active\u002Fsymptomatic brain metastases\n* Pleural effusion, ascites, or pericardial effusion requiring repeated puncture\u002Fdrainage (≥2 times\u002Fmonth) or causing significant symptoms within 28 days prior to randomization\n* Clinically significant severe cardiovascular disease\n* Stroke, transient ischemic attack (TIA), or other severe cerebrovascular disease within 6 months prior to randomization\n* High-risk factors for bleeding or perforation\n* Concurrent interstitial lung disease, radiation pneumonitis, or immune-mediated pneumonitis that is clinically significant and requires treatment\n* Major acute or chronic infectious disease\n* Other poorly controlled systemic disease\n* Prior targeted therapy against KRAS or RAS\n* History of organ transplantation or planned organ transplantation\n* Receipt of a live attenuated vaccine within 28 days prior to randomization, or planned vaccination with a live attenuated vaccine during the trial drug treatment period\n* Pregnant or lactating women\n* Any other condition that, in the investigator's judgment, makes the participant unsuitable for study participation","ALL","18 Years",{"count":101,"type":102},368,"ESTIMATED","INTERVENTIONAL",[105],"PHASE3","This is a Phase III trial. All enrolled subjects are patients with metastatic colorectal cancer (mCRC) harboring KRAS G12D mutations who have previously received systemic therapy. The study aims to evaluate and compare the efficacy of GFH375 in combination with cetuximab versus the investigator's choice of treatment in participants with KRAS G12D mutant refractory metastatic colorectal cancer (mCRC).",[108],"Colorectal Cancer","NOT_YET_RECRUITING","2026-11-01",{"date":112,"type":113},"2026-11-03","ACTUAL",{"date":115,"type":102},"2026-11",{"date":117,"type":102},"2030-05",{"name":5,"class":6}]